Abstract
Today, Klebsiella pneumoniae strains are sophisticatedly associated with the transmission of KPC, and ST11 clones carrying KPC-2 are an important target for anti-infective clinical therapy, posing a very high threat to patients. To present the detailed genetic features of two KPC-2 core structures of F94_plasmid pA, the whole genome of K. pneumoniae strain F94 was sequenced by nanopore and illumina platform, and mobile genetic elements associated with antibiotic-resistance genes were analyzed with a series of bioinformatics methods. K. pneumoniae strain F94, identified as a class A carbapenemase-resistant Enterobacteriaceae, was resistant to most tested antibiotics, especially to low-levels of ceftazidime/avibactam (avibactam ≤ 4 mg/L), owing to overexpression of the two KPC-2 in F94_plasmid pA. However, strain F94 was sensitive to high-levels of ceftazidime/avibactam (avibactam ≥ 8 mg/L), which correlated with further inhibition of ceftazidime hydrolysis by the KPC-2 enzyme due to the multiplication of avibactam. Collinearity analysis indicated that multi-drug resistance (MDR) regions of plasmids with the tandam repeats of two or more KPC-2 core structures share highly similar structures. This study characterized the MDR region of the F94_ plasmid pA as homologous to plasmids pKPC2_090050, pKPC2_090374, plasmid unnamed 2, pC2414-2-KPC, pKPC2-020037, pBS1014-KPC2, pKPC-J5501, and pKPC2-020002, which contained the tandem repeats of one, two, or more KPC-2 core structures, providing insight into the evolution of multidrug resistance in K. pneumoniae. An alternative theoretical basis for exploring the tandem repeats of two or more KPC-2 core structures was developed by analyzing and constructing the homologous sequence of F94_ plasmid pA.
Similar content being viewed by others
Introduction
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is wreaking havoc around the world and represents a significant threat to public health1. This threat has been emphasized by international bodies2, especially in North and South America, Southern and Eastern Europe, Israel, and China3. Clone group 258 K. Pneumoniae strains, including ST11, ST258, and ST512, have been implicated in KPC spread4,5, particularly ST114,6. The KPC-containing plasmids are major genetic determinants of antimicrobial resistances7,8. Because of its ability to spread rapidly, the KPC-2-carrying ST11 clone is an important target of anti-infective clinical therapy and poses a very significant threat to patients8.
Ceftazidime/avibactam, a novel β-lactam/β-lactamase inhibitor combination with activity against KPC or OXA-48-like carbapenemases9, is currently one of the last antibacterial agents available to treat infections of CRKP10. However, K. pneumoniae strains with ceftazidime/avibactam resistance are rapidly emerging11. This is a new area challenging clinicians and researchers. Another greater and more worrying issue is that the combination of high virulence and carbapenem resistance has led to the emergence and global spread of possible “superbugs”, such as prevalent K. pneumoniae clone ST1112. Consequentially, serious and fatal community-acquired and hospital-related infections are emerging13,14,15, and these need to be actively prevented.
In accordance with the literature6, sequence analysis and annotation showed that plasmids carrying blaKPC-2 from clinical K. pneumoniae isolates harbor other antibiotic-resistance determinants, e.g., blaTEM-1, blaCTX-M-65, blaCTX-M-90, and rmtB, which can lead to multidrug resistance. Different mobile elements, mostly IS26, are located upstream and downstream of antimicrobial multi-resistance (AMR) genes and might play important roles in AMR horizontal transfer.
To date, at least 11 types of plasmid vectors encoding KPC-2 have been discovered, of which the four most populous plasmid types are IncR, IncF, IncN, and IncX16. Tn3 family transposons are crucial mobile genetic elements of the KPC-2 core structures17. Overall, three genetic types of Tn3 family transposons are distributed among plasmid-carried blaKPC-2 resistance determinants18: (i) Tn4401-like transposons with “istB-istA-ISKpn7-blaKPC-2-ISKpn6” as the core structure, such as pKPC-NY79 (GenBank accession no JX104759.1); (ii) Tn1722-transposons with “ISKpn27-blaKPC-2-ΔISKpn6-korC” as the core structure, such as pKP048 (FJ628167.2), p628-KPC (KP987218.1), and pKPC-LK30 (KC405622.1); (iii) and those with “IS26-tnpR-ISKpn27-blaKPC-2-ΔISKpn6” as the core structure, such as pECN580 (KF914891.1). In this study, we compared and analyzed MDR region of the F94_plasmid bearing KPC-2 with those of related plasmids, characterized the KPC-2 core structure of the plasmid, and explored the evolutionary mechanisms of plasmid formation.
Materials and methods
Bacterial strains and sequencing of the 16S rRNA gene
K. pneumoniae F94 strain was isolated from a sputum sample of a patient in Taizhou Municipal Hospital affiliated with Taizhou University in 2021. EC600 and Escherichia coli DH5α were employed as hosts for cloning. The nearly complete 16S rRNA gene of the strain was amplified by PCR using the following primers: AGAGTTTGATYMTGGCTCAG (forward) and TACCTTGTTACGACTT (Y, T, or C; M, A, or C) (reverse). The Taq enzyme was a 3:1 mixture of Fermentas Taq:Pfu (ThermoFisher Scientific, Burlington, VT, USA), and the 30 mL reaction consisted of 1.5 U of enzyme. Amplification was performed using a temperature program, including initial denaturation at 94 °C for 3 min, 30 cycles of denaturation at 94 °C for 40 s, annealing at 50 °C for 40 s, extension at 72 °C for 1 min, and final extension at 72 °C for 5 min. The length of the amplicon was about 1500 bp19. The PCR products were identified by bidirectional sequencing.
Experiments of conjugal transfer and plasmid transfer
Bacterial plasmid DNA of the F94 strain was extracted using a plasmid extraction kit (TaKaRa, Dalian, China) according to the manufacturer's instructions. Plasmids were transferred from the F94 isolate into E. coli EC600 and DH5a by conjugation transfer and electroporation, respectively. 1000 μg/mL rifampicin and 2 μg/mL imipenem were used appropriately when selecting electroporators or transconjugates harboring the blaKPC marker.
Detection of Class A serine carbapenemase and Class B metallo β-lactamase
Class A carbapenemase and class B metallo β-lactamase were detected using the paper-disc agar-diffusion method recommended by CLSI20. The tested bacterium was prepared in a 0.5 McFarland turbidity bacterial suspension evenly spread on an Mueller–Hinton (MH) agar plate; then four imipenem discs were affixed to the surface of the agar. No liquid was added to one disc. The 3-aminophenylboronic acid (APB) solution was added to another disc at an initial concentration of 30 mg/L, gradually adding 10 μL at a time until the final concentration reached 300 μg/piece. EDTA solution was gradually added to the third piece using 10 μL of the initial concentration of 0.1 mmol/L until a final concentration of 292 μg/disc was achieved. Then APB solution (final concentration: 300 μg/disc) and EDTA solution (final concentration: 292 μg/disc) were added to all four discs at the same time. The diameters of inhibition zones were measured after overnight incubation.
The results were interpreted as follows: (1) If the diameter of the inhibition zone for the imipenem disc with APB solution was more than or equal to 5 mm more than that of the single imipenem disc, it was determined that the tested strain contained class A carbapenemase. (2) If the diameter of the inhibition zone for the imipenem disc with EDTA solution was more than 5 mm different from that of the imipenem disc alone, it was confirmed that the tested strain produced class B carbapenemase. (3) If the diameter of inhibition zone for imipenem disc onto which APB + EDTA were added simultaneously was more than 5 mm different from that of the imipenem disc alone, the tested strain carried class A carbapenemase + class B metal β-lactamase. (4) If the difference between inhibition zone diameters for imipenem discs containing enzyme inhibitor and imipenem disc alone was less than 5 mm, the tested strain did not bear class A or B carbapenemase.
Antimicrobial susceptibility test
Bacterial resistance was detected by Bio-Merieux VITEK2 and antibiotic dilution test (MICs), and the results were determined in accordance with the 2020 CLSI Guidelines20. More than Twenty-one antibiotics and antibiotics + enzyme inhibitors were detected (Table 1), and E. coli ATCC 25922 was used as the quality control strain.
Sequencing and sequence assembly
Genomic sequencing of strain F94 was performed on a PacBio RSII sequencer (Pacific Biosciences, CA, USA) using a sheared DNA library with an average size of 15 kb (range 10 kb to 20 kb), and on a Illumina HiSeq X sequencer (Illumina, San Diego, USA) using a paired-end library with an average insert size of 400 bp (range 150 bp to 600 bp). To improve the reliability of data processing, raw data from HiSeq X platform were trimmed to obtain the high-quality clean reads (clean data) by Canu v1.8 (https://canu.readthedocs.io/en/latest/index.html). The paired-end short Illumina reads and the long Nanopore reads were “de novo” assembled using Unicycler v0.4.5 (https://github.com/rrwick/Unicycler). Finally, accurate DNA sequences in the study were obtained. Finally, accurate DNA sequences in the study were obtained.
Sequence annotation and comparison in detail
Open reading frames (orfs) and pseudogenes were predicted using RAST2.021, BLASTP/BLASTN22, UniProtKB/Swiss-Prot23, and RefSeq databases24. Resistance genes, mobile elements, and other features were annotated using online databases such as CARD25, ResFinder26, ISfinder27, INTEGRALL28, and the Tn Number Registry29. MUSCLE 3.8.3130 and BLASTN were used for multiple and pairwise sequence comparisons. The sequences of each KPC-2 core structure were compared using Mega1131. After removing all gaps, the evolutionary tree was constructed in RAxML32 and embellished with ggtree33, and the recombination of KPC-2 core structure sequences was detected by ClonalFrameML34. Visualization of genome comparisons was performed using genoPlotR35. Circos plot of plasmids were drawn with CGView36. All figures were edited using Inkscape 0.48.1 (https://inkscape.org/en).
Nucleotide sequence accession numbers
The sequence of F94_plasmid pA was deposited on the GenBank database with an accession number ofOM144977. Comparative analysis and characteristic analysis were performed for F94_plasmid pA and related plasmids including pKPC2_090050, pKPC2_090374, Plasmid unnamed 2, pC2414-2-KPC, pKPC2-020037, pBS1014- KPC2, pKPC-J5501, and pKPC2-020002, for which the GenBank accession numbers were CP043370.1, CP066536.1, CP023942.1, CP039820.1, CP036372.1, MT269822.1, OL891656.1, and CP028541.2, respectively (Table 2).
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Taizhou University, Zhejiang, China, and written informed consent was obtained from each of the participants in accordance with the Declaration of Helsinki. The rights of the research subjects were protected throughout, and we confirm that this study was conducted in our school. The use of human specimens and all related experimental protocols were approved by the Committee on Human Research of Taizhou University, and the protocols were carried out in accordance with approved guidelines.
Results
Antimicrobial susceptibility test, enzymatic property, and transferrable feature
The 16S rRNA sequence and species identification of strain F94 as Klebsiella pneumoniae were confirmed using BLAST and average nucleotide homology analysis of the genomic sequence. Results for the drug-susceptibility test of F94 strain were shown in Table 1. In particular, the strain also showed resistance to low-levels of ceftazidime/avibactam (avibactam ≤ 4 mg/L); nevertheless, when increasing the avibactam concentration, the strain showed sensitivity to high-levels of ceftazidime/avibactam (avibactam ≥ 8 mg/L), which was directly related to the increased avibactam further inhibiting the hydrolysis of ceftazidime by the KPC-2 enzyme.
Enzyme characterization confirmed that the strain F94, which belonged to the ST11 clone, contained only class A carbapenemase. After bacterial conjugative transfer and electroporation assays, transconjugant integrating the F94_plasmid pA could be recovered, demonstrating the successful transfer of F94_plasmid pA with class A carbapenemase, thus confirming the transferable properties of the F94_plasmid pA.
Overview of structural features for F94_plasmid pA
The F94_plasmid pA was 172.743 kb in length and carried two replication genes repA1 and repA2, and contained two multidrug resistance MDR1 and MDR2 regions, harboring resistance genes such as blaCTX-M, blaTEM, fosA, rmtB and two blaKPC-2, merA and four pathogenic virulence genes such as two LEE-encoded T3SS, CdpA and Rpn (pilW) (Fig. S1). Overall, there might be altered localization, insertion or deletion of multidrug-resistant gene among Tn2, Tn3 and TnAs3. (Figs. 2, 4 and Fig. S2).
Comparison of F94_plasmid pA with related plasmids: pKPC2_090050, pKPC2_090374, plasmid unnamed 2, pC2414-2-KPC, and pKPC2-020037, pBS1014-KPC2, pKPC-J5501, pKPC2-020002
The sequence structures of pKPC2_090050 and pKPC2_090374 were almost identical, except that the former was 4-bp shorter, and both had one MDR region of approximately 21.9 kb in length (Fig. 1A). F94_Plasmid pA carried two MDR regions and had a regional overlapping with pKPC2_090374, which containd only one MDR region. pKPC2_090374, and F94_Plasmid pA also showed a high degree of identity, including a reverse sequence of 90–135 kb, with the corresponding region in pKPC2_090374 (Fig. 1A). Similarly, Plasmid unnamed 2 also contained two MDRs and the structure in the opposite direction and was highly consistent with F94_Plasmid pA (Fig. 1A). pC2414-2-KPC displayed a highly inverted structure and shared two MDR regions with plasmid unnamed 2 (Fig. 1A). Both pKPC2-020002 and pKPC2-020037 featured two MDRs with identical structures in the overall and overlapping regions in MDR2 (Fig. 1B). pKPC2-020037 showed excellent identity with F94_Plasmid pA in both MDRs (Fig. 1B). pKPC-J5501, with only one MDR, displayed a shorter sequence length than the above plasmids and had partial reverse identity with pBS1014-KPC2 MDR1 and MDR2 (Fig. 1B).
Both pKPC2_090050 and pKPC2_090374 encompassed only one MDR, including a single blaKPC-2 core structure, blaCTX-M gene, rmtB gene, and Tn2 structure. The blaKPC-2 core structure was characterized by IS26 + ISKpn6 + blaKPC-2 + ISKpn27 + tnpR + IS26. The Tn2 structure contained tnpR_1 + IS26 + IS1294 + tnpR + blaTEM-1, showing that tnpR was divided into two parts with IS26 + IS1294 (two discontinuous sequences) inserted in the middle (Fig. S2A). The MDR1 of F94_Plasmid pA and pC2414-2-KPC involved a rough rmtB gene and Tn2 structure, in which tnpR was divided into two or three parts with IS26 to IS1294 inserted between them (two discontinuous sequences) (approximately 10.1 kb) in F94_Plasmid pA (Fig. 2A) or IS26 to IS1294 (two discontinuous sequences) (approximately 6.2 kb between tnpR_1 and tnpR_2) and IS26 + hypothetical protein + fosA + IS26 + IS1294 (two discontinuous sequences) (approximately 3.7 kb between tnpR and tnpR_1) in pC2414-2-KPC (Fig. S2A). MDR1 of Plasmid unnamed 2 harbored a rough rmtB gene and Tn2 structure, in which tnpR was divided into three parts interrupted with IS26 to IS1294 (5.5 kb or so) (Fig. S2A), and IS26 + IS1294 (approximately 0.51 kb between tnpR and tnpR_1) (Fig. S2A).pKPC2-020002 was nearly identical to pKPC2-020037 in MDR1, including a Tn2 structure and rmtB gene. The Tn2 structure was divided into three parts separated by IS26 to IS1294 (approximately 6.2 kb between tnpR_2 and tnpR_1) and IS26 to IS1294 (approximately 1.3 kb between tnpR_1 and tnpR) in pKPC2-020002 (Fig. S2B), or IS26 to IS1294 (approximately 6.2 kb between tnpR_3 and tnpR_2) and IS26 to IS1294 (approximately 1.3 kb between tnpR_2 and tnpR_1) in pKPC2-020037 (Fig. S2B). The MDR1 of pBS1014-KPC2 contained a rough rmtB gene and Tn2 structure, in which tnpR was divided into two parts interrupted by IS26 to IS1294 (approximately 8.2 kb between tnpR_3 and tnpR_1) (Fig. S2B). pKPC-J5501 only consisted of one MDR that was partially consistent with the reverse of MDR1 in pBS1014-KPC2. pKPC-J5501 included a rmtB gene and Tn2 structure, in which tnpR was divided into two parts separated by IS1294 (two discontinuous sequences) + IS26 + IS1294 + IS26 between tnpR_1 and tnpR_3 (Tn3 remnant) (Fig. S2B).
The MDR2 of F94_plasmid pA and other plasmids (pKPC2-020037, pBS1014-KPC2, pKPC-J5501, pKPC2-020002) comprised almost identical structures, with two or three core KPC-2 structures, where pKPC2-020002 contained three core KPC-2 structures and the others two. pKPC-J5501 harbored only one MDR, but the KPC-2 core structure was reversed compared with the others (Fig. 2B).
Comparative analysis of all plasmids with two or more core KPC-2 structures
In addition to having exactly the same KPC-2 core structure as pKPC2-020037, pBS1014-KPC2, pKPC-J5501, and pKPC2-020002 (Fig. 2B), F94_plasmid pA also shared a similar KPC-2 core structure with pKPC2_115011, pSH9-KPC, pPA30_2, pU1121, pSRRSH1002-KPC, pYLH6_p3, pHS20R14-KPC-2, strain PA30 chromosome, and strain XHKPN39. Besides above plasmids with the tandem repeats of two or more KPC-2 core structures, some plasmids also comprised two or more KPC-2 core structures but separated by only 2–5 genes or orfs (Table 3, Fig. 5), while others possessed two or more KPC-2 core structures that were spaced apart from each other and located at different sites of the plasmids (Table 3).
The KPC-2 core structures of these plasmids, including F94_plasmid pA, pKPC2-020037, pBS1014-KPC2, pKPC-J5501, pKPC2-20002, pKPC2_115011, pSH9-KPC, pPA30_2, pU1121, pSRRSH1002-KPC, pYLH6_p3, and pHS20R14- KPC-2, were determined to be intrinsically evolutionarily related through a study of molecular evolutionary genetics and comparative visual analysis (Fig. 3A). The KPC-2 core structural sequences 1 to 12 shown in Fig. 3A belonged to the above mentioned plasmid sequences, while sequences 13 to 23 represented phylogenic nodes. Through a further investigation of the KPC-2 core structure of the above plasmids, we found that the inserted phylogenetic node 17 was a 4.723 kb located from 1 bp to 4.723 kb; accordingly, phylogenetic node 17 was inserted into the KPC-2 core structure located from 771 bp to 5.513 kb (Fig. S3). It can be deduced from Fig. 3A that the insertion of the KPC-2 core structure of phylogenic node 17 directly led to the formation of two or more KPC-2 core structures for real plasmids 4, 5–10 and phylogenic nodes 18 and 19–23 (Fig. 3A). It was determined that a KPC-2 core structure sequence had been inserted in F94_plasmid pA at 73.953 kb to 78.695 kb (Fig. S3), which happened to be directly connected to another KPC-2 core structure to form the tandem repeats of two KPC-2 core structures (10.197-kb length) (Figs. 4A, S3). Additionally, we found that the KPC-2 core structure of phylogenic node 16 had undergone a recombination event at 4.451 kb to 4.723 kb (Fig. 3B), which had directly led to changes before the formation of real plasmids 2 (CP107842.1) and 3 (MK882885.1) but caused no changes in F94_plasmid pA.
Mechanism of F94_plasmid pA formation
By comparing F94_plasmid pA with Tn2 and Tn3, we discovered that MDR1 in F94_ plasmid pA was formed by inserting a different insert sequence (IS) or gene with Tn2 as a backbone, and MDR2 was developed from Tn3 residues and TnAs3 and included a direct tandem repeats of the two KPC-2 core structures as a backbone. F94_plasmid pA was inserted at 73,953 kb to 78,695 kb and combined with another complete KPC-2 core structure, forming the tandem repeats of two KPC-2 core structures (Fig. 4A).
Discussion
KPC-producing Klebsiella pneumoniae is widely disseminated worldwide, and ceftazidime/avibactam is one of the few drugs that can effectively treat infections of these bacteria37. However, reports of resistance to different concentrations of ceftazidime/avibactam have progressively increased18,38,39,40. A susceptibility test for strain F94 in this study ascertained it also had resistance to ceftazidime/avibactam (avibactam ≤ 4 mg/L), but sensitivity to hight-levels of ceftazidime/avibactam (avibactam ≥ 8 mg/L) (Table 1) . One reason might be related to the tandem repeats of two KPC-2 core structures in F94_plasmid pA, which increased the expression of KPC carbapenemases. In addition, hight-levels of avibactam (avibactam ≥ 8 mg/L) further reduced the hydrolytic efficacy of KPC-2 enzyme on ceftazidime, thus making ceftazidime/avibactam exhibit a sensitive effect on F94 strain41. Also, the amino acid at site 179 of the two blaKPC-2 remained D (Asp) and was not substituted, therefore, we hypothesized that the strain should still manifest sensitivity to specific concentrations of ceftazidime/avibactam41,42, which was consistent with our results for high-levels of ceftazidime/avibactam (avibacta ≥ 8 mg/L). In general, three main causes of ceftazidime/avibactam resistance in CRKP strains have been reported worldwide, comprising the co-production of metallo-β-lactamases, the enhanced expression of KPC carbapenemases, and amino acid substitutions/deletions/ insertions in key sites of KPC carbapenemases39,41,43.
To accurately investigate the emergence of two or more KPC-2 core structures in the study, we compared all plasmids on GenBank containing two or more KPC-2 core structures based on the tandem repeats of two KPC-2 core structures of the F94_ plasmid pA listed in Table 3, and established the intrinsic relationship model described in Fig. 3 by interrogation analysis. When a plasmid carrying a single KPC-2 core structure, such as pKPC2_090374, lost its KPC-2 core structure, it evolved into an intermediate plasmid structure 1 containing a Tn2 structure. If the intermediate plasmid structure 1 also combined with another plasmid carrying a KPC-2 core structure, it became an intermediate plasmid structure 2 containing both a Tn2 structure and a KPC-2 core structure. Under suitable conditions, the lost KPC-2 core structure was integrated into the site of the KPC-2 core structure (Fig. 4A) of intermediate plasmid structure 2, thus, the tandem repeats of two KPC-2 core structures, as in F94_plasmid pA, was realized (Fig. 4B). Figure 5 illustrated the features and geographic locations for two or more KPC-2 core structures that were of the tandam repeats or repeats of two or more KPC-2 core structure separated by 2–5 genes or orfs, with which the prevalence could be better characterized.
Although the plasmid recombination of multicopy blaKPC-2 had been reported44, however, it illustrated several KPC-2 core structures similar to the tandem repeats formed by “ISKpn27(8)-blaKPC-2-ΔISKpn6-korC”18, while we inferred that the tandem repeats formed by “IS26-tnpR-ISKpn27-blaKPC-2-ΔISKpn6”18, unlike the above18,44. After collating all analysis results, we concluded that (1) the formation of F94_plasmid pA was the result of the long-term evolution of Tn2, Tn3, TnAs3, and IS through the insertion, deletion, and colonization of drug-resistance genes (Figs. 2, 4, S2); (2) Tracing their evolution revealed that the tandam repeats of two KPC-2 core structures of F94_ plasmid pA were inserted and recombined from the phylogenic node 17 into a KPC-2 core structure at 1 bp to 4.723 kb, and through a series of evolutionary steps, a daughter F94_ plasmid pA was established in which the KPC-2 core structure was inserted into another KPC-2 core structure at 73.953 kb to 78.695 kb at some time (Figs. 3, 4, S3). (3) The plasmids with two or more KPC-2 core structures in tandem repeats had intrinsic and precise connections with other plasmids involving two or more KPC-2 core structures separated by 2–5 genes or orfs (Table 3, Fig. 5), which is illustrated in Fig. 3.
Conclusions
This study characterized the tandem repeats of two KPC-2 core structures in F94_plasmid pA and demonstrated that pKPC2_090050, pKPC2_090374, plasmid unnamed 2, pC2414-2-KPC, F94_plasmid pA, pKPC2-020037, pBS1014-KPC2, pKPC-J5501, and pKPC2-020002 had homologous sequence structures in their MDR regions, providing a unique and reliable theoretical basis for exploring the formation mechanism of the tandem repeats of two or more KPC-2 core structures. It is reasonable to assume that novel plasmids will be discovered carrying 4, 6 to 10, or even more the tandem repeats of KPC-2 core structure, or harboring 4, 6 to 10, or even more repeats of the KPC-2 core structure separated by 2–5 genes or orfs, which will pose an even greater challenge to human multidrug-resistance therapy.
Data availability
The datasets of F94_plasmidA generated during the current study are available in the GenBank repository as OM144977.
References
Wang, Y., Wang, J., Wang, R. & Cai, Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J. Glob. Antimicrob. Resist. 22, 18–27 (2020).
World Health Organization (WHO). Guidelines for the Prevention and Control of Carbapenem Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities (World Health Organization, 2017).
Logan, L. K. & Weinstein, R. A. The epidemiology of carbapenem-resistant Enterobacteriaceae: The impact and evolution of a global menace. J. Infect. Dis. 215(Suppl 1), S28-36 (2017).
Chen, L. et al. Carbapenemase-producing Klebsiella pneumoniae: Molecular and genetic decoding. Trends Microbiol. 22(12), 686–696 (2014).
Pitout, J. D. D., Nordmann, P. & Poirel, L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob. Agents Chemother. 59(10), 5873–5884 (2015).
Li, P. et al. Convergence of carbapenem resistance and hypervirulence in a highly-transmissible ST11 clone of K. pneumoniae: An epidemiological, genomic and functional study. Virulence 12(1), 377–388 (2021).
Oteo, J. et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J. Antimicrob. Chemother. 71(12), 3392–3399 (2016).
Cheng, L. et al. Clonal dissemination of KPC-2 producing Klebsiella pneumoniae ST11 clone with high prevalence of oqxAB and rmtB in a tertiary hospital in China: results from a 3-year period. Ann. Clin. Microbiol. Antimicrob. 15(1), 1 (2016).
Van Duin, D. & Bonomo, R. A. Ceftazidime/avibactam and ceftolozane/tazobactam: Second-generation β-lactam/β-lactamase inhibitor combinations. Clin. Infect. Dis. 63, 234–241 (2016).
Sheu, C. C., Chang, Y. T., Lin, S. Y., Chen, Y. H. & Hsueh, P. R. Infections caused by carbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front. Microbiol. 10, 80 (2019).
Shields, R. K. et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob. Agents Chemother. 61(3), 16 (2017).
Chen, L. & Kreiswirth, B. N. Convergence of carbapenem-resistance and hyper-virulence in Klebsiella pneumoniae. Lancet Infect. Dis. 18(1), 2–3 (2018).
Holt, K. E. et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc. Natl. Acad. Sci. USA 112(27), e3574-3581 (2015).
Paczosa, M. K. & Mecsas, J. Klebsiella pneumoniae: Going on the offense with a strong defense. Microbiol. Mol. Biol. Rev. 80(3), 629–661 (2016).
Nordmann, P., Cuzon, G. & Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9(4), 228–236 (2009).
Martins, W. M. B. S. et al. Clinical and molecular description of a high-copy IncQ1 KPC-2 plasmid harbored by the international ST15 Klebsiella pneumoniae clone. MSphere. 5(5), e00756-e820 (2020).
David, S. et al. Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among Klebsiella pneumoniae. Proc. Natl. Acad. Sci. USA 117(40), 25043–25054 (2020).
Chen, Q. et al. A small KPC-2-producing plasmid in Klebsiella pneumoniae: Implications for diversified vehicles of carbapenem resistance. Microbiol. Spectr. 10(3), e0268821 (2022).
Frank, J. A. et al. Critical evaluation of two primers commonly used for amplification of bacterial 16S rRNA genes. Appl. Environ. Microbiol. 74(8), 2461–2470 (2008).
CLSI. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100 32nd edn. (CLSI, 2022).
Brettin, T. et al. RASTtk: A modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci. Rep. 5, 8365 (2015).
Boratyn, G. M. et al. BLAST: A more efficient report with usability improvements. Nucleic Acids Res. 41, W29-33 (2013).
Boutet, E. et al. UniProtKB/Swiss-Prot, the manually annotated section of the UniProt KnowledgeBase: How to use the entry view. Methods Mol. Biol. 1374, 23–54 (2016).
O’Leary, N. A. et al. Reference sequence (RefSeq) database at NCBI: Current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 44(D1), D733-745 (2016).
Liang, Q. et al. Sequencing and comparative genomics analysis of the IncHI2 plasmids pT5282-mphA and p112298-catA and the IncHI5 plasmid pYNKP001-dfrA. Int. J. Antimicrob. Agent. 49(6), 709–718 (2017).
Zankari, E. et al. Identification of acquired antimicrobial resistance genes. J. Antimicrob. Chemother. 67(11), 2640–2644 (2012).
Siguier, P., Perochon, J., Lestrade, L., Mahillon, J. & Chandler, M. ISfinder: The reference centre for bacterial insertion sequences. Nucleic Acids Res. 34, D32-36 (2006).
Moura, A. et al. INTEGRALL: A database and search engine for integrons, integrases and gene cassettes. Bioinformatics 25(8), 1096–1098 (2009).
Roberts, A. P. et al. Revised nomenclature for transposable genetic elements. Plasmid 60(3), 167–173 (2008).
Edgar, R. C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32(5), 1792–1797 (2004).
Tamura, K., Stecher, G. & Kumar, S. MEGA11: Molecular evolutionary genetics analysis version 11. Mol. Biol. Evol. 38(7), 3022–3027 (2021).
Stamatakis, A. RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30(9), 1312–1313 (2014).
Yu, G. Using ggtree to visualize data on tree-like structures. Curr. Protoc. Bioinform. 69(1), e96 (2020).
Didelot, X. & Wilson, D. J. ClonalFrameML: Efficient inference of recombination in whole bacterial genomes. PLoS Comput. Biol. 11(2), e1004041 (2015).
Guy, L., Kultima, J. R. & Andersson, S. G. E. genoPlotR: Comparative gene and genome visualization in R. Bioinformatics 26(18), 2334–2335 (2010).
Stothard, P. & Wishart, D. S. Circular genome visualization and exploration using CGView. Bioinformatics 21(4), 537–539 (2005).
Tumbarello, M. et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin. Infect. Dis. 68(3), 355–364 (2019).
Gaibani, P. et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J. Antimicrob. Chemother. 73(6), 1525–1529 (2018).
Sun, L. et al. Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background. J. Antimicrob. Chemother. 75(10), 3072–3074 (2020).
Gaibani, P., Re, M. C., Campoli, C., Viale, P. L. & Ambretti, S. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: Epidemiology and genomic characterization. Clin. Microbiol. Infect. 26(4), 516.e1–4 (2020).
Zhang, P. et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin. Microbiol. Infect. 26(1), 124.e1–4 (2020).
Shi, Q. et al. Multiple novel ceftazidime- avibactam-resistant variants of blaKPC-2-positive Klebsiella pneumoniae in two patients. Microbiol. Spectr. 10(3), e0171421 (2022).
Coppi, M. et al. Ceftazidime- avibactam resistance associated with increased blaKPC-3 gene copy number mediated by pKpQIL plasmid derivatives in sequence type 258. Antimicrob. Agents Chemother. 64(4), e01816-e1819 (2020).
Dong, N. et al. An IncR plasmid harbored by a hypervirulent carbapenem-resistant Klebsiella pneumoniae strain possesses five tandem repeats of the blaKPC-2::NTEKPC-Id fragment. Antimicrob. Agents Chemother. 63(3), e01775-e1818 (2019).
Acknowledgements
This work was supported by Zhejiang Health Department of China (2023KY1319). We thank Suzanne Leech, PhD, from Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing the English text of a draft of this manuscript.
Author information
Authors and Affiliations
Contributions
Conceived and designed the experiments: D.W. Performed the experiments: all authors. Analyzed the data: D.W. and W.W. Contributed to the writing of the manuscript: D.W. and L.M. Read and approved the final manuscript: all authors.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ma, L., Wang, W., Qu, Y. et al. Characterization of the two tandem repeats for the KPC-2 core structures on a plasmid from hospital-derived Klebsiella pneumoniae. Sci Rep 13, 12049 (2023). https://doi.org/10.1038/s41598-023-38647-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-023-38647-z
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.